Stockholm, Sweden

Sophia Hober

This inventor holds 12 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Ge Healthcare Bio-Sciences Ab, Affibody Ab, Cytiva Bioprocess R&d Ab. Active years: 2004-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sophia Hober. Retrieved from https://idiyas.com/inventor/sophia-hober

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 58.3


 

Average Co-Inventor Count = 1.5

ph-index = 9

Forward Citations = 205(Granted Patents)


Company Filing History:


Years Active: 2004-2023

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Sophia Hober - Innovative Inventor from Stockholm

Introduction: Sophia Hober is a pioneering inventor based in Stockholm, Sweden, known for her groundbreaking contributions to the field of biotechnology.

Latest Patents: Sophia Hober holds several patents in the area of protein engineering and biotechnology, with her most recent patent focusing on a novel method for protein purification.

Career Highlights: With a career spanning over two decades, Sophia Hober has made significant advancements in the development of protein-based therapeutics, earning her recognition as a leading expert in the field.

Collaborations: Throughout her career, Sophia Hober has collaborated with top research institutions and biopharmaceutical companies to further the application of her innovative technologies in the healthcare industry.

Conclusion: Sophia Hober's dedication to innovation and her relentless pursuit of scientific excellence continue to inspire the next generation of inventors and researchers in the field of biotechnology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…